Corrigendum: Drug therapy in anticoagulation: which drug for which patient?
Carolyn M Millar and Mike A Laffan
DOI: https://doi.org/10.7861/clinmedicine.17-4-347a
Clin Med August 2017 Carolyn M Millar
AImperial College, London, UK and consultant haematologist, Imperial College Healthcare NHS Trust, London, UK
Roles: clinical senior lecturer
Mike A Laffan
BImperial College, London, UK and honorary consultant in haematology, Imperial College Healthcare NHS Trust, London, UK
Roles: professor of haemostasis and thrombosis
Clinical Medicine 2016;17:233–44
There were errors in the drug doses published in Table 1 and Table 5.
In Table 1, the correct dose of edoxaban should have been listed as 60 mg od4 for NVAF and 60 mg od (following ≥5 days LMWH)4 for VTE; the correct dose for rivaroxaban in ACS is 2.5 mg bd, not 2.5 mg od as originally listed.
In Table 5, the correct dose for dabigatran is 110 mg bd and the correct standard dose for rivaroxaban is 20 mg od.
The corrected tables are published below.
There was an omission in Table 2 – the confidence interval for the primary endpoint SSE for edoxaban was 97.5%.
View this table:
View this table:
- © Royal College of Physicians 2017. All rights reserved.
Article Tools
Corrigendum: Drug therapy in anticoagulation: which drug for which patient?
Carolyn M Millar, Mike A Laffan
Clinical Medicine Aug 2017, 17 (4) 347-349; DOI: 10.7861/clinmedicine.17-4-347a
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.